Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
View Patent ↗The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
1. A method for inducing an immune response against an influenza virus, comprising administering to a subject an effective amount of a vaccine formulation comprising a genetically engineered attenuated influenza virus and a physiologically acceptable excipient, in which the genome of the genetically engineered attenuated influenza virus encodes a truncated NS1 protein of amino acid residues 1 to 99 of the NS1 protein of the same or a different influenza virus strain, so that the genetically engineered attenuated influenza virus has an impaired interferon antagonist phenotype, wherein the amino terminus amino acid is number 1.
2. A method for inducing an immune response against an influenza virus, comprising administering to a subject an effective amount of a vaccine formulation comprising an attenuated influenza virus and a physiologically acceptable excipient, wherein the attenuated influenza virus is influenza strain NS1/99.
3. The method of claim 1 , wherein the impaired interferon antagonist phenotype is measured in cell culture.
4. The method of claim 1 , wherein the impaired interferon antagonist phenotype is measured in embryonated eggs.
5. The method of claim 1 , wherein the genetically engineered attenuated influenza virus is an influenza A virus.
6. The method of claim 1 , wherein the genetically engineered attenuated influenza virus is an influenza B virus.
7. The method of claim 1 , wherein the NS1 protein is derived from influenza strain NS1/99.
8. The method of claim 1 or 2 , wherein the effective amount comprises a dose of 10 4 to 5×10 6 pfu of the attenuated influenza virus.
9. The method of claim 1 or 2 , wherein the subject is a human.
10. The method of claim 1 or 2 , wherein the formulation is administered to the subject intranasally, intratracheally, orally, intradermally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.
11. The method of claim 10 , wherein the formulation is administered to the subject intranasally.
12. The method of claim 10 , wherein the formulation is administered to the subject intratracheally.
13. The method of claim 10 , wherein the formulation is administered to the subject orally.
14. The method of claim 10 , wherein the formulation is administered to the subject intradermally.
15. The method of claim 10 , wherein the formulation is administered to the subject intramuscularly.
16. The method of claim 10 , wherein the formulation is administered to the subject intraperitoneally.
17. The method of claim 10 , wherein the formulation is administered to the subject intravenously.
18. The method of claim 10 , wherein the formulation is administered to the subject subcutaneously.
19. A method for inducing an immune response against an influenza virus, comprising administering to a subject an effective amount of a vaccine formulation comprising a genetically engineered attenuated influenza virus and a physiologically acceptable excipient, in which the genome of the genetically engineered attenuated influenza virus encodes a truncated NS1 protein of amino acid residues 1 to 130, amino acid residues 1 to 120, amino acid residues 1 to 110, amino acid residues 1 to 100, amino acid residues 1 to 90, amino acid residues 1 to 70, or amino acid residues 1 to 60 of the NS1 protein of the same or a different influenza virus strain, so that the genetically engineered attenuated influenza virus has an impaired interferon antagonist phenotype, wherein the amino terminus amino acid number is 1.
20. The method of claim 19 , wherein the genetically influenza virus genome encodes a truncated NS1 protein of amino acid residues 1 to 130 of the NS1 protein of the same or a different influenza virus strain.
21. The method of claim 19 , wherein the genetically influenza virus genome encodes a truncated NS1 protein of amino acid residues 1 to 120 of the NS1 protein of the same or a different influenza virus strain.
22. The method of claim 19 , wherein the genetically influenza virus genome encodes a truncated NS1 protein of amino acid residues 1 to 110 of the NS1 protein of the same or a different influenza virus strain.
23. The method of claim 19 , wherein the genetically influenza virus genome encodes a truncated NS1 protein of amino acid residues 1 to 100 of the NS1 protein of the same or a different influenza virus strain.
24. The method of claim 19 , wherein the genetically influenza virus genome encodes a truncated NS1 protein of amino acid residues 1 to 90 of the NS1 protein of the same or a different influenza virus strain.
25. The method of claim 19 , wherein the genetically influenza virus genome encodes a truncated NS1 protein of amino acid residues 1 to 70 of the NS1 protein of the same or a different influenza virus strain.
26. The method of claim 19 , wherein the genetically influenza virus genome encodes a truncated NS1 protein of amino acid residues 1 to 60 of the NS1 protein of the same or a different influenza virus strain.
27. The method of claims 19 , 20 , 21 , 22 , 23 , 24 , 25 or 26 , wherein the impaired interferon antagonist phenotype is measured in cell culture.
28. The method of claims 19 , 20 , 21 , 22 , 23 , 24 , 25 or 26 , wherein the impaired interferon antagonist phenotype is measured in embryonated eggs.
29. The method of claims 19 , 20 , 21 , 22 , 23 , 24 , 25 or 26 , wherein the genetically engineered attenuated influenza virus is an influenza A virus.
30. The method of claims 19 , 20 , 21 , 22 , 23 , 24 , 25 or 26 , wherein the genetically engineered attenuated influenza virus is an influenza B virus.
31. The method of claims 19 , 20 , 21 , 22 , 23 , 24 , 25 or 26 , wherein the NS1 protein is derived from influenza A/PR/8/34 virus.
32. The method of claim 19 , wherein the effective amount comprises a dose of 10 4 to 5×10 6 pfu of the attenuated influenza virus.
33. The method of claims 19 , 20 , 21 , 22 , 23 , 24 , 25 or 26 , wherein the subject is a human.
34. The method of claims 19 , 20 , 21 , 22 , 23 , 24 , 25 or 26 , wherein the formulation is administered to the subject intranas ally, intratracheally, orally, intradermally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.
35. The method of claim 34 , wherein the formulation is administered to the subject intranasally.
36. The method of claim 34 , wherein the formulation is administered to the subject intradermally.
37. The method of claim 34 , wherein the formulation is administered to the subject intramuscularly.